Gast ::
| 001 | 852074 | ||
| 005 | 20230512150827.0 | ||
| 024 | 7 | _ | |a eva473244 |2 HSB |
| 024 | 7 | _ | |a 0007-1188 |2 ISSN |
| 024 | 7 | _ | |a 0366-0826 |2 ISSN |
| 024 | 7 | _ | |a 1476-5381 |2 ISSN |
| 024 | 7 | _ | |a 2056-8177 |2 ISSN |
| 024 | 7 | _ | |a SCOPUS:2-s2.0-85112739023 |2 SCOPUS |
| 024 | 7 | _ | |a WOS:000685876500001 |2 WOS |
| 024 | 7 | _ | |a 10.1111/bph.15588 |2 doi |
| 024 | 7 | _ | |a pmid:34409595 |2 pmid |
| 024 | 7 | _ | |a 10.18154/RWTH-CONV-249162 |2 datacite_doi |
| 037 | _ | _ | |a RWTH-CONV-249162 |
| 041 | _ | _ | |a English |
| 100 | 1 | _ | |a Weiskirchen, Ralf |0 P:(DE-82)IDM05726 |b 0 |e Corresponding author |u rwth |
| 245 | _ | _ | |a Physalin B attenuates liver fibrosis via suppressing LAP2 alpha-HDAC1 mediated deacetylation of glioma-associated oncogene 1 and hepatic stellate cell activation |h online, print |
| 260 | _ | _ | |a Malden, MA |b Wiley |c 2021 |
| 336 | 7 | _ | |0 0 |2 EndNote |a Journal Article |
| 336 | 7 | _ | |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |a Journal Article |b journal |m journal |
| 336 | 7 | _ | |2 BibTeX |a ARTICLE |
| 336 | 7 | _ | |2 DRIVER |a article |
| 336 | 7 | _ | |2 DataCite |a Output Types/Journal article |
| 336 | 7 | _ | |2 ORCID |a JOURNAL_ARTICLE |
| 591 | _ | _ | |a Germany |
| 773 | _ | _ | |0 PERI:(DE-600)2029728-2 |a 10.1111/bph.15588 |n 20 |p 4045-4047 |t British journal of pharmacology |v 178 |x 2056-8177 |
| 856 | 4 | _ | |u https://publications.rwth-aachen.de/record/852074/files/852074.pdf |y OpenAccess |
| 909 | C | O | |o oai:publications.rwth-aachen.de:852074 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a RWTH Aachen |0 I:(DE-588b)36225-6 |k RWTH |b 0 |6 P:(DE-82)IDM05726 |
| 914 | 1 | _ | |y 2021 |
| 915 | 1 | _ | |0 StatID:(DE-HGF)0031 |2 StatID |a Peer reviewed article |x 0 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2021-02-02 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BRIT J PHARMACOL : 2019 |d 2021-02-02 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2021-02-02 |w ger |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-02 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2021-02-02 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b BRIT J PHARMACOL : 2019 |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-02-02 |
| 920 | 1 | _ | |0 I:(DE-82)526000-3_20140620 |k 526000-3 |l Institut und Lehrstuhl für Molekulare Pathobiochemie, experimentelle Gentherapie und klinische Chemie |x 0 |
| 970 | _ | _ | |a eva473244 |
| 980 | _ | _ | |a I:(DE-82)526000-3_20140620 |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a journal |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|